Trial Profile

A Study of Zanubrutinib in Patients With Primary Immune Thrombocytopenia (ITP)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanubrutinib (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Therapeutic Use

Most Recent Events

07 Oct 2023 Phase amended from I/II to II.
07 Oct 2023 Status changed from recruiting to completed.
15 Jun 2023 Results (n=40, between Feb 1, 2022, and Dec 30, 2022) assessing the efficacy and safety of zanubrutinib in patients with corticosteroid-resistant or relapsed Immune thrombocytopenia, presented at the 28th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com